IRCT20231108059994N1已完成3 期
Studying the effect of Rivaroxaban 2.5 mg daily on Arteriovenous hemodialysis graft maintenance and thrombosis
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Dependence on hemodialysis or the need for hemodialysis in the near future
- •Installing a new artificial vein for dialysis
排除标准
- •Recent major bleeding (within the last 6 months) that is defined as follows: bleeding requiring transfusion, bleeding in a high-risk area (retroperitoneal or intracranial), bleeding that caused a decrease in body volume or hospitalization, or bleeding that caused Hg drop is more than 2 gr/dl.
- •Inability to take oral medication
- •Anticoagulant use for another reason
- •Life expectancy of less than two months or waiting for recovery of renal failureOpen in
研究者
相似试验
招募中
2 期
Treatment with rivaroxaban compared with warfarin in patients with acute coronary syndromeAcute coronary syndrome.Other acute ischemic heart diseasesIRCT20210614051574N9Esfahan University of Medical Sciences60
招募中
2 期
Assessment of the impact of Rivaroxaban in peripheral artery disease (PAD) of the lower extremitiesIRCT20231117060086N1Ahvaz University of Medical Sciences112
招募中
2 期
Evaluating the efficacy and safety of rivaroxaban comparing to warfarin in patients with chronic thromboembolic pulmonary hypertension (CTEPH) following endartrectomy surgeryChronic Thrombo Embolic Pulmonary Hypertension(CTEPH).Chronic Thromboembolic Pulmonary Hypertension.I27. 24IRCT20151227025726N22Shahid Beheshti University of Medical Sciences96
尚未招募
不适用
Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PADPeripheral Arterial DiseaseNCT04305028Poznan University of Medical Sciences100
已完成
不适用
A randomised controlled trial with rivaroxaban and apixaban in the treatment for venous thromboembolism in cancer patientsVenous thromboembolism with cancer patientsJPRN-UMIN000026600Chiba Cancer Center100